Download Files:
PF-06263276
$195 – $1,440
Products Details
Product Description
– PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively[1].
Web ID
– HY-101024
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C31H31FN8O2
References
– [1]Jones P, et al. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J Med Chem. 2017 Jan 26;60(2):767-786.
CAS Number
– 1421502-62-6
Molecular Weight
– 566.63
Compound Purity
– 99.38
SMILES
– FC1=C(O)C=C(CC)C(C2=CC(NN=C3C4=NC5=C(CN(C(C6=NC=C(N7CCCCC7)N=C6)=O)CC5)N4)=C3C=C2)=C1
Clinical Information
– Phase 1
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 33.33 mg/mL (ultrasonic)
Target
– JAK
Isoform
– JAK1;JAK2;JAK3;Tyk2
Pathway
– Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
